Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2024) 102 138 | DOI: 10.1530/endoabs.102.138

1Department of Nuclear Medicine, LMU Klinik Munich; 2Department of Radiology, LMU Klinik Munich; 3Department of Endocrinology, LMU Klinik Munich


Introduction: Somatostatin receptor (SSTR)-targeted PET/CT is widely used for diagnosing and monitoring pheochromocytoma and paraganglioma (PPGLs). This study aims to evaluate the potential of the novel SSTR-targeted tracer [18F]-SiTATE in diagnosing PPGLs by comparing imaging parameters with tumor marker levels and secretory activity in a small cohort of patients diagnosed with PPGL.

Methods: All patients with histologically confirmed PPGL who presented for [18F]-SiTATE-PET/CT at LMU Klinikum between October 2020 and February 2024, along with hormonal laboratory analysis of both plasma and 24-hour urine samples within up to 100 days, were included. Metabolic tumor volume (MTV) was assessed using a threshold of mean standard uptake value (SUVmean) of 5.0. Total lesion uptake (TLU) was assessed as SUVmean × MTV. Correlation was tested using Spearman’s rank correlation test.

Results: Thirty-four out of 39 patients (median age: 55, range: 5-83) were included in this study, with 5 patients with cervical PGL excluded. Twenty-one patients had metastatic disease. There was a moderate correlation between TLU and MTV and urinary dopamine (r = 0.50-0.51, P < 0.05) as well as norepinephrine (r = 0.50-0.54, P < 0.05). TLU and MTV also moderately correlated with serum chromogranin-A levels (r = 0.60, P < 0.01). Additionally, a moderate correlation was found between TLU and MTV with plasma normetanephrine and 3-methoxytyramine (r = 0.52-0.56, P < 0.01).

Conclusion: MTV and TLU measured with [18F]-SiTATE-PET/CT correlate well with serum chromogranin-A and specific catecholamine pathway biomarkers in urine and plasma, reflecting metabolic tumor activity. Despite the limitations of the relatively small cohort, our results suggest that TLU in [18F]-SiTATE-PET/CT could be used as an imaging biomarker for monitoring disease progression and secretory activity in patients with PPGL.

Volume 102

ESE Young Endocrinologists and Scientists (EYES) 2024

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.